Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

K M Biglan; E R Dorsey; R V V Evans; C A Ross; S Hersch; I Shoulson; W Matson; K Kieburtz; Huntington Study Group Pre-2CARE Investigators

doi:10.3233/JHD-2012-120007

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

J Huntingtons Dis. 2012;1(1):65-9. doi: 10.3233/JHD-2012-120007.

Authors

K M Biglan¹, E R Dorsey², R V V Evans³, C A Ross⁴, S Hersch⁵, I Shoulson⁶, W Matson⁷, K Kieburtz³; Huntington Study Group Pre-2CARE Investigators

Collaborators

Huntington Study Group Pre-2CARE Investigators:
H Christopher Hyson, Karl Kieburtz, Ira Shoulson, Michael McDermott, Bernard Ravina, Elisabeth A de Blieck, Merit E Cudkowicz, Robert J Ferrante, Peter Como, Sam Frank, Carol Zimmerman, Merit E Cudkowicz, Kimberly Ferrante, Kristyn Newhall, Danna Jennings, Tammie Kelsey, Francis Walker, Vicki Hunt, Susan Daigneault, Michele Goldstein, Joseph Weber, Arthur Watts, M Flint Beal, Susan E Browne, Linda J Metakis

Affiliations

¹ Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. [email protected]
² Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
³ Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
⁴ Departments of Psychiatry, Neurology, Neuroscience and Pharmacology, Johns Hopkins University, Baltimore, MD, USA.
⁵ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
⁶ Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Department of Neurology, Georgetown University, Washington, D.C., USA.
⁷ Boston University School of Medicine, Boston, MA, USA.

Abstract

We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.

Keywords: 8OHdG; Huntington disease; coenzyme Q10; oxidative injury.

Publication types

Clinical Trial
Research Support, N.I.H., Extramural

MeSH terms

8-Hydroxy-2'-Deoxyguanosine
Adult
Aged
Biomarkers / blood
Case-Control Studies
Deoxyguanosine / analogs & derivatives*
Deoxyguanosine / blood
Female
Humans
Huntington Disease / drug therapy*
Male
Middle Aged
Oxidative Stress / drug effects
Ubiquinone / adverse effects
Ubiquinone / analogs & derivatives*
Ubiquinone / blood
Ubiquinone / therapeutic use
Young Adult

Substances

Biomarkers
Ubiquinone
8-Hydroxy-2'-Deoxyguanosine
coenzyme Q10
Deoxyguanosine

Abstract

Publication types

MeSH terms

Substances

Grants and funding